Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Allo-QuadCAR01-T |
| Synonyms | |
| Therapy Description |
Limited information is currently available on Allo-QuadCAR01-T, a putative allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and MS4A1 (CD20) (Dec 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Allo-QuadCAR01-T | Allo QuadCAR01-T|Allo-QuadCAR01 T-cells | CD19 Immune Cell Therapy 73 CD20 Immune Cell Therapy 15 | Limited information is currently available on Allo-QuadCAR01-T, a putative allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and MS4A1 (CD20) (Dec 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07284433 | Phase Ib/II | Allo-QuadCAR01-T Cyclophosphamide + Fludarabine | Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies (QUADvance) | Not yet recruiting | DEU | 0 |